Minimal Residual Disease (MRD) Testing with Dr. Rafael Fonseca
Spotify%20--%3e%3csvg%20version='1.1'%20id='Livello_1'%20xmlns='http://www.w3.org/2000/svg'%20xmlns:xlink='http://www.w3.org/1999/xlink'%20x='0px'%20y='0px'%20width='300px'%20height='300px'%20viewBox='0%200%20300%20300'%20enable-background='new%200%200%20300%20300'%20xml:space='preserve'%3e%3cg%20id='XMLID_632_'%3e%3clinearGradient%20id='XMLID_2_'%20gradientUnits='userSpaceOnUse'%20x1='150'%20y1='0'%20x2='150'%20y2='300'%3e%3cstop%20offset='0'%20style='stop-color:%23F452FF'/%3e%3cstop%20offset='1'%20style='stop-color:%23832BC1'/%3e%3c/linearGradient%3e%3cpath%20id='XMLID_662_'%20fill-rule='evenodd'%20clip-rule='evenodd'%20fill='url(%23XMLID_2_)'%20d='M294.1,260c-2.9,7.4-9.6,17.8-19.2,25.2%20c-5.5,4.2-12.1,8.3-21.1,11c-9.6,2.9-21.5,3.8-36.3,3.8h-135c-14.8,0-26.6-1-36.3-3.8c-9-2.7-15.6-6.7-21.1-11%20c-9.5-7.3-16.3-17.8-19.2-25.2C0.1,245.1,0,228.2,0,217.5l0,0v-135l0,0C0,71.8,0.1,54.9,5.9,40c2.9-7.4,9.6-17.8,19.2-25.2%20c5.5-4.2,12.1-8.3,21.1-11C55.9,1,67.7,0,82.5,0l0,0h135l0,0c14.8,0,26.6,1,36.3,3.8c9,2.7,15.6,6.7,21.1,11%20c9.5,7.3,16.3,17.8,19.2,25.2c5.9,14.9,5.9,31.9,5.9,42.5v135C300,228.2,299.9,245.1,294.1,260z'/%3e%3cg%3e%3cpath%20id='XMLID_657_'%20fill='%23FFFFFF'%20d='M175.7,181.1c-0.4-3.6-1.6-6.2-4-8.6c-4.5-4.7-12.4-7.8-21.7-7.8c-9.3,0-17.2,3-21.7,7.8%20c-2.3,2.5-3.6,5-4,8.6c-0.8,7-0.3,13,0.5,22.7c0.8,9.2,2.3,21.5,4.2,33.9c1.4,8.9,2.5,13.7,3.5,17.1c1.7,5.6,7.8,10.4,17.5,10.4%20c9.7,0,15.9-4.9,17.5-10.4c1-3.4,2.1-8.2,3.5-17.1c1.9-12.5,3.4-24.7,4.2-33.9C176.1,194.1,176.5,188.1,175.7,181.1z'/%3e%3cpath%20id='XMLID_655_'%20fill='%23FFFFFF'%20d='M174.6,130.1c0,13.6-11,24.6-24.6,24.6s-24.6-11-24.6-24.6c0-13.6,11-24.6,24.6-24.6%20S174.6,116.6,174.6,130.1z'/%3e%3cpath%20id='XMLID_653_'%20fill='%23FFFFFF'%20d='M149.7,33.2C92.3,33.4,45.3,80,44.5,137.4c-0.6,46.5,29.1,86.3,70.6,100.9%20c1,0.4,2-0.5,1.9-1.5c-0.5-3.6-1.1-7.2-1.5-10.8c-0.2-1.3-1-2.3-2.1-2.9c-32.8-14.3-55.7-47.2-55.3-85.3%20c0.5-50,41.3-90.7,91.2-91.1c51.1-0.4,92.8,41,92.8,92c0,37.7-22.8,70.1-55.3,84.4c-1.2,0.5-2,1.6-2.1,2.9%20c-0.5,3.6-1,7.2-1.5,10.8c-0.2,1.1,0.9,1.9,1.9,1.5c41.1-14.4,70.6-53.6,70.6-99.6C255.5,80.5,208,33.1,149.7,33.2z'/%3e%3cpath%20id='XMLID_651_'%20fill='%23FFFFFF'%20d='M147.3,68.2c-37.4,1.4-67.4,32.3-67.9,69.7c-0.3,24.6,12,46.4,30.9,59.3%20c0.9,0.6,2.2-0.1,2.2-1.2c-0.3-4.3-0.3-8.1-0.1-12.1c0.1-1.3-0.4-2.5-1.4-3.4c-11.5-10.8-18.5-26.2-18.1-43.2%20c0.8-30,24.9-54.4,54.9-55.6c32.6-1.3,59.4,24.9,59.4,57.1c0,16.4-7,31.2-18.1,41.7c-0.9,0.9-1.4,2.1-1.4,3.4%20c0.2,3.9,0.1,7.7-0.1,12c-0.1,1.1,1.2,1.9,2.2,1.2c18.6-12.7,30.9-34.2,30.9-58.4C220.8,98.9,187.5,66.6,147.3,68.2z'/%3e%3c/g%3e%3c/g%3e%3c/svg%3e){kind=small}
Apple Podcasts
YoutubeLearn what Minimal Residual Disease (MRD) testing is, how it should be used and why you should be talking to your doctor about it in this insightful show with myeloma expert Rafael Fonseca, MD, Chief Innovation Officer at the Mayo Clinic.
Dr. Fonseca shares how the test has evolved from a research tool to gain helpful insights in routine clinic care. In this show he explains how MRD testing is even changing the way clinical trials are run. Find answers to the most common questions about MRD testing in this valuable HealthTree for Multiple Myeloma podcast episode.
Join us on March 11 (virtual meeting) to learn more about MRD testing.
Jenny Ahlstrom
Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of the HealthTree Foundation.
Rafael Fonseca, MD
Rafael Fonseca, MD, is the Getz Family Professor of Cancer, Professor of Medicine, interim Executive Director of the Mayo Clinic Comprehensive Cancer Center, Director for Innovation and Transformational Relationships, and a consultant in the Division of Hematology/Oncology at the Mayo Clinic in Arizona. Dr. Fonseca’s practice has focused on the diagnosis and treatment of plasma cell disorders and leading the multiple myeloma team in its effort to understand the disease and its impact on patients. In his laboratory, Dr. Fonseca has led his team of researchers in concentrating on the genetic nature of the clonal cells of plasma cell disorders. He is also interested in myeloma bone disease, prognostic markers and development of new therapies. Throughout his training and career, Dr. Fonseca has received numerous awards and honors, including the Young Investigator Award in Hematology (Celgene – Achievement Awards for Clinical Research in Hematology), the Damon Runyon-Walter Winchell Clinical Investigator Award, and the International Waldenström Macroglobulinemia Research Award. Most notably, he is a Mayo Clinic Distinguished Investigator, the highest academic distinction given to investigators at his institution. Dr. Fonseca holds memberships and serves in positions for organizations such as the American Society of Clinical Oncology, the American Society of Hematology, the American Association for Cancer Research, and the International Myeloma Society. His research has been funded by the National Cancer Institute (R01, P01, SPORE), the Leukemia and Lymphoma Society, the Multiple Myeloma Research Fund, and the Damon Runyon Cancer Research Fund, for which he also serves as a clinical investigator. Dr. Fonseca serves as reviewer and in editorial capacities for medical publications including Blood, Lancet, Nature Medicine, Cancer Cell, Leukemia, and the New England Journal of Medicine, among others. He is a frequent reviewer of grants and sits on the SPORE grant review panel. He has given many national and international presentations as a visiting professor and has authored more than 300 articles, book chapters, editorials, abstracts, and letters.
